Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Researchers find link between obesity and disease relapse in pediatric Hodgkin lymphoma patients

Obesity has been identified as an adverse risk factor for survival in many adult and childhood cancers, but not in pediatric Hodgkin lymphoma, the most common cancer in adolescents.

7 Jun 2016

Nivolumab drug shows better response rate in metastatic bladder cancer patients

The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical trial results from The University of Texas MD Anderson Cancer Center.

6 Jun 2016

Initiatives to improve adolescent, young adult cancer outcomes justified

Analysis of the EUROCARE-5 data shows that although survival for adolescents and young adults with cancer has improved overall, the survival rates for certain malignancies still lag behind those for children.

28 May 2016

Sylvester researchers test new KTE-C19 therapy for patients with aggressive non-Hodgkin's lymphoma

Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine are testing a novel cellular immunotherapy approach to treating patients with diffuse large B-cell lymphoma who have failed standard therapy.

25 May 2016

NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

It is estimated that more than 72,000 people in the United States will be diagnosed with Non-Hodgkin's Lymphomas (NHL) in 2016. The sixth leading cancer diagnosis in U.S. men and women, NHL has more than 30 sub-types, each featuring unique treatment choices and challenges.

30 Apr 2016

Gut bacteria linked to risk of bloodstream infections after chemotherapy

A new study led by researchers at the University of Minnesota and Nantes University Hospital in France shows that the bacteria in people's gut may predict their risk of life-threatening blood infections following high-dose chemotherapy.

29 Apr 2016

Novel combination of cancer drugs can have therapeutic impact on diffuse large B-cell lymphoma

New research from Roswell Park Cancer Institute shows that promising cancer drugs used in combination can have significant therapeutic impact on a particularly aggressive subtype of diffuse large B-cell lymphoma (DH-DLBCL) in preclinical studies. The researchers will present their findings at the American Association for Cancer Research (AACR) Annual Meeting 2016, to be held April 16-20 in New Orleans.

21 Apr 2016

MicroRNA controls tumor cell proliferation in most aggressive large B-cell lymphoma

A recent study by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine showed that a microRNA called miR-181a dampens signals from the cancer-driving NFκB protein pathway in the most aggressive large B-cell lymphomas (DLBCL). By reducing NFκB signaling, miR-181a controls tumor cell proliferation and survival and could be the target of novel therapies. The study was published in the journal Blood.

2 Apr 2016

Secondary non-Hodgkin's lymphoma a concern for CML patients using TKIs

Patients with chronic myeloid leukaemia who use the tyrosine kinase inhibitor imatinib may be three to four times more likely to develop non-Hodgkin's lymphoma than the general population, study findings indicate.

17 Mar 2016

Early screening with MRIs can reduce risk of breast cancer mortality for survivors of childhood HL

Researchers at Princess Margaret Cancer Centre have confirmed in a screening effectiveness study that early screening with MRIs can reduce breast cancer mortality for female survivors of childhood Hodgkin's lymphoma (HL) who received chest radiation.

1 Mar 2016

Researchers launch clinical trials to test novel cellular-immunotherapy to treat three types of blood cancer

Cancer immunology is based upon boosting the body's own immune system to vanquish malignancies. It is among the fastest growing areas of oncology research. Researchers at UC San Diego Moores Cancer Center have launched three clinical trials to test the safety and efficacy of a novel cellular-immunotherapy that uses modified T cells - one of the immune system's primary weapons - to treat three different types of blood cancer that often defy existing therapies.

24 Feb 2016

Higher body weight, taller stature during adolescence increase NHL risk

A new analysis indicates that higher body weight and taller stature during adolescence increase the risk of developing Non-Hodgkin's Lymphoma (NHL), a type of cancer of the lymphatic system. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society.

22 Feb 2016

HUYA, Eisai sign exclusive license agreement for HBI-8000 in Japan and other Asian countries

HUYA Bioscience International President, CEO, Executive Chairman & Founder Dr. Mireille Gillings announced that Eisai Co., Ltd. has acquired from HUYA an exclusive license agreement for HBI-8000 in Japan, South Korea, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Singapore.

1 Feb 2016

Young African Americans, Hispanics fare worse when faced with Hodgkin lymphoma

African American and Hispanic adolescents and young adults fare far worse than their white counterparts when faced with a mostly curable type of cancer, Hodgkin lymphoma, a study by a UC Davis epidemiologist has found.

30 Jan 2016

African-American pediatric lymphoma patients have inferior outcomes compared to white and Hispanic peers

Researchers from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine today published a study showing that African-American pediatric Hodgkin lymphoma patients have inferior overall survival to their white and Hispanic peers.

25 Jan 2016

New study finds significant racial disparity in patients with HIV and Hodgkin lymphoma

A new study finds a significant racial disparity within a doubly troubled population of patients: those with HIV and Hodgkin lymphoma. In such cases, blacks are at significantly higher risk than whites of not receiving treatment for the cancer that in many cases would be effective.

11 Jan 2016

Rich Pharmaceuticals obtains FDA approval to begin Phase 1/2 study in AML and MDS patients

Rich Pharmaceuticals, Inc. is pleased to announce that the Company has received approval from the U.S. Food and Drug Administration to commence its Phase 1/2 clinical for the treatment of Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients.

28 Dec 2015

HBI-8000 granted orphan drug designation in Japan for treatment of peripheral T-cell lymphoma

HUYA Bioscience International, Founder, CEO & Executive Chair, Dr. Mireille Gillings today announced that the Ministry of Health, Labour and Welfare granted HBI-8000 orphan drug designation in Japan for peripheral T-cell lymphoma (PTCL).

22 Dec 2015

New study examines single 'transformer' proteins involved in cancer

A new study led by scientists at The Scripps Research Institute and St. Jude Children's Research Hospital shows how a protein involved in cancer twists and morphs into different structures.

22 Dec 2015

Innovative Phase II trial evaluates effectiveness of diabetes medication for lymphoma

Cancer, it could be said, grows like a weed: rapidly, invasively, and with devastating impact on the place it infests. Also like a weed, cancer can't grow on its own — it needs nourishment, which it drains from the human body, just as weeds take nutrients in the soil away from other plants.

13 Dec 2015

Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Researchers find link between obesity and disease relapse in pediatric Hodgkin lymphoma patients

Nivolumab drug shows better response rate in metastatic bladder cancer patients

Initiatives to improve adolescent, young adult cancer outcomes justified

Sylvester researchers test new KTE-C19 therapy for patients with aggressive non-Hodgkin's lymphoma

NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

Gut bacteria linked to risk of bloodstream infections after chemotherapy

Novel combination of cancer drugs can have therapeutic impact on diffuse large B-cell lymphoma

MicroRNA controls tumor cell proliferation in most aggressive large B-cell lymphoma

Secondary non-Hodgkin's lymphoma a concern for CML patients using TKIs

Early screening with MRIs can reduce risk of breast cancer mortality for survivors of childhood HL

Researchers launch clinical trials to test novel cellular-immunotherapy to treat three types of blood cancer

Higher body weight, taller stature during adolescence increase NHL risk

HUYA, Eisai sign exclusive license agreement for HBI-8000 in Japan and other Asian countries

Young African Americans, Hispanics fare worse when faced with Hodgkin lymphoma

African-American pediatric lymphoma patients have inferior outcomes compared to white and Hispanic peers

New study finds significant racial disparity in patients with HIV and Hodgkin lymphoma

Rich Pharmaceuticals obtains FDA approval to begin Phase 1/2 study in AML and MDS patients

HBI-8000 granted orphan drug designation in Japan for treatment of peripheral T-cell lymphoma

New study examines single 'transformer' proteins involved in cancer

Innovative Phase II trial evaluates effectiveness of diabetes medication for lymphoma

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in